BRAF V600E MutationEarly Phase 1NCT06610682
A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
A Early Phase 1 study testing Plixorafenib and Retifanlimab in people with BRAF V600E Mutation, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins at 2 sites in United States.
Trial summary
The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutant glioma refractory to prior therapies. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- BRAF V600E Mutation
- What is being tested?
- Plixorafenib and Retifanlimab
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 2 sitesUnited States
- Study dates
- 7 Apr 2025to 30 Jun 2028
- Phase
- Early Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient must have received prior BRAF and/or MEK inhibitor therapy.
- Prior RAF dimer disruptor or pan-RAF inhibitor not allowed
- Prior immunotherapy allowed
- The following intervals from previous treatments should have elapsed prior to enrollment:
- BRAFi/MEKi should be stopped 2 weeks prior to surgery
- Patients must be maintained on a stable or decreasing dose of systemic corticosteroid regimen (no increase for 5 days) prior to screening MRI. No maximum dose. Topical and inhaled steroid treatment is allowed.
Show all 42Show fewer
- Patient must have received prior BRAF and/or MEK inhibitor therapy.
- Prior RAF dimer disruptor or pan-RAF inhibitor allowed,
- Prior immunotherapy not allowed (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathway).
- The following intervals from previous treatments should have elapsed prior to first infusion:
- BRAFi/MEKi should be stopped 7 days prior to first retifanlimab infusion and at least 2 weeks prior to surgery.
- Patients must be maintained on a stable (<4mg daily dexamethasone) or decreasing dose of systemic corticosteroid regimen (no increase for 5 days) prior to screening MRI. Topical and inhaled steroid treatment is allowed.
- Histologic diagnosis of a primary CNS tumor with documented BRAF-V600E mutation by a CLIA approved DNA or RNA-based sequencing test (NGS or RNAseq). Immunohistochemistry alone is insufficient.
- Karnofsky performance status ≥ 70.
- Patient is 18 years of age or older.
- Measurable disease by RANO 2.0 criteria on screening MRI. Leptomeningeal disease allowed.
- Willing to submit archival tumor sample if available.
- The following intervals from previous treatments should have elapsed prior to either day of surgery (for Arm A) or first infusion of Retifanlimab (for Arm B):
- 12 weeks from the completion of radiation.
- 8 weeks from an anti-VEGF therapy
- 4 weeks from a nitrosourea chemotherapy
- 2 weeks or 5 half-lives from any investigational (not FDA-approved) agents or FDA-approved non-nitrosourea chemotherapy (whichever is shorter)
- Patients must have the following organ and marrow function:
- Absolute neutrophil count >1,000/mcL
- Platelets >100,000/mcL
- Hemoglobin > 9 g/dL
- Total bilirubin < 1.5 x institutional upper limit of normal (ULN) OR total bilirubin >1.5 × ULN with direct bilirubin < 1.5 × ULN;
- AST (SGOT) and ALT (SGPT) < 2.5 x institutional ULN
- PT or PTT < 1.5 x institutional ULN
- Creatinine ≤ 1.5 x institutional ULN OR
- Estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73 m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
- Patient must be able to provide written informed consent.
- All adverse events related to prior therapies (chemotherapy; radiotherapy; surgery) must have resolved to Grade 1 or baseline except for
- Alopecia (Grade ≤2)
- Sensory neuropathy (Grade ≤2)
- Lymphopenia (Grade <2)
- Other adverse events that have resolved to Grade ≤2 that, according to the clinical judgment of the investigator, do not constitute a safety risk to the participant.
- Ability to swallow and retain orally administered medications, including a liquid suspension.
- Female participants of childbearing potential (defined as all females who have experienced menarche and who are not postmenopausal or surgically sterile) must have a negative serum pregnancy test prior to study start. Surgical sterility (methods inclusive of hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) or post-menopausal state (amenorrhea for ≥24 months without an alternative medical cause and FSH ≥30 mIU/mL) must be confirmed. Female participants of childbearing potential must agree to use highly effective contraception or practice true abstinence (defined as refraining from heterosexual intercourse during the entire specified period) and not to donate ova from screening through 30 days after the last dose of plixorafenib or 120 days after last dose of retifanlimab. Highly effective contraception is defined as 1) intrauterine device, 2) abstinence, or 3) combined estrogen and progesterone or progesterone only containing implants, injectables, transdermal, or intravaginal contraceptives.
- Male participants must also be documented to be surgically sterile or agree to use adequate contraception and not to donate sperm from screening until 30 days after the last dose of plixorafenib or 120 days after last dose of retifanlimab.
- Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder. Patients with other malignancies must be disease-free for > 2 years.
- Life expectancy equal or greater than six months.
Who cannot join
- Prior RAF dimer disruptor or pan-RAF inhibitor.
- Prior immunotherapy (of note prior RAF dimer-disruptor or pan-RAF inhibitor is allowed).
- Known history of clinically significant autoimmune disease that, in the opinion of the investigator, may be exacerbated by immune checkpoint blockade (e.g., multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease), with the following exceptions: Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment (subjects with a history of flares requiring systemic treatment are excluded), or other autoimmune conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- Daily systemic steroids > 4mg daily dexamethasone or equivalent.
- Have received a live vaccine within 28 days before the planned start of study treatment.
- Current use of any other standard or investigational agents (excepting tumor treating fields).
Show all 21Show fewer
- Known co-occurring NF1 and/or RAS-related alteration known to cause resistance.
- Known hypersensitivity to plixorafenib, retifanlimab or to excipients.
- Current use of a prohibited medication (including herbal medications, supplements, or foods), as described in Section 5.6, or use of a prohibited medication ≤ 7 days prior to first infusion of retifanlimab.
- Impairment in gastrointestinal function or disease that may significantly alter the absorption of oral plixorafenib (such as ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
- Clinically significant cardiovascular disease including, but not limited to the following:
- History of acute coronary syndromes (including myocardial infarction or unstable angina), coronary artery bypass grafting, coronary angioplasty or stenting ≤ 180 days prior to start date;
- Congestive heart failure requiring treatment (New York Heart Association Grade > 2);
- History or presence of clinically significant cardiac arrhythmias (including resting bradycardia, uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia);
- QTcF interval ≥ 480 ms.
- History of recent (≤ 90 days) thromboembolic or cerebrovascular event such as transient ischemic attack, cerebrovascular accident, or hemodynamically significant (massive or sub-massive) deep vein thrombosis or pulmonary emboli (DVT/PE). Note: Patients with DVT/PE that does not result in hemodynamic instability may enroll as long as the participants are anticoagulated for at least 4 weeks. Note: Patients with DVT/PE related to indwelling catheters or other procedures may enroll.
- Known history of any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection, and/or detectable virus. Subjects with previously treated viral hepatitis and undetectable virus may be eligible.
- Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements, are ineligible.
- Pregnant women are excluded from this study because the effects of plixorafenib or retifanlimab on a fetus are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with plixorafenib, breastfeeding should be discontinued if the mother is treated on study.
- Contraindication to ventricular reservoir placement or biospecimen collection.
- Current use of strong inhibitors or inducers of CYP3A.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Principal Investigator, MD contact
United States2 sites, 2 recruiting
- Recruiting
Johns Hopkins
Baltimore, Maryland, 21231
Karisa Schreck, MD, 410-955-8837
- Not yet recruiting
NYU Langone Health Perlmutter Cancer Center Ambulatory Care Center
New York, New York, 10016
Research Nurse, RN, 212-731-6267
About this study
Official title: A Trial to Evaluate Deoxyribonucleic) in BRAF (V-raf Murine Sarcoma Viral Oncogene Homolog B1)-Altered Glioma During Treatment With Plixorafenib Alone or With Retifanlimab
The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutant glioma refractory to prior therapies.
Read the detailed description
This clinical trial is designed as a pilot, signal-finding study to demonstrate the feasibility of detecting ctDNA at C1D1 (baseline) and pre-C2 (week 4) (primary endpoint), as well as correlating with disease status as per radiographic response (RR; secondary endpoint). In addition, the investigators will generate preliminary data for the activity of plixorafenib co-administered with retifanlimab in this heavily-pretreated population. Patients with measurable (by RANO 2.0), recurrent BRAF-V600E mutant glioma will be screened and consented for the study prior to surgery. Patients will undergo pre-operative MRI and clinically-indicated resection or biopsy (specific approach as per treating neurosurgeon) for confirmation of progression and characterization of potential acquired resistance alterations. All patients will have a ventricular reservoir placed at time of surgery with CSF and plasma sampling.
Arm A: Patients will start the study drug (plixorafenib 900mg daily 30 minutes after a full meal or meal supplement) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth continuously for 28-day cycles until progressive disease or up to 24 cycles. MRI will be performed post-operatively (between surgery and start of study drug) for evaluation of measurable disease, at the beginning of Cycle 2, then at the beginning of every odd cycle. Blood and CSF samples will be obtained on day of surgery, C1D1 (baseline), pre-C2 (week 4) and with every odd cycle up to and including C7 and EOT.
Arm B: This arm will evaluate the safety and biological effect of plixorafenib in combination with retifanlimab. Participants will receive one dose of retifanlimab prior to surgery. Following surgery, the participants will start plixorafenib 7-28 days post-operatively, when clinically stable. Retifanlimab (administered by IV every 28 days) will be restarted after one cycle of plixorafenib or after the 2nd cycle of plixorafenib per physician discretion. Patients will take the drugs in 28-day cycles until progressive disease or up to 24 cycles. MRI, blood, CSF and other study assessments will be performed as for Arm A.
- Conditions
- BRAF V600E Mutation
- Being tested
- Plixorafenib, Retifanlimab
- Keywords
- BRAF,, BRAF V600E mutant, Plixorafenib, Retifanlimab, recurrent
- Medical subject headings
- Recurrence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlixorafenibDrug
Patients will start the study drug (plixorafenib 900mg daily 30 minutes after a full meal or meal supplement) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth continuously for 28-day cycles until progressive disease or up to 24 cycles. MRI will be performed post-operatively (between surgery and start of study drug) for evaluation of measurable disease, at the beginning of Cycle 2, then at the beginning of every odd cycle. Blood and CSF samples will be obtained on day of surgery, C1D1 (baseline), pre-C2 (week 4) and with every odd cycle up to and including C7 and EOT.
RetifanlimabDrug
Investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutant glioma refractory to prior therapies.
| Study group | Role | What they receive |
|---|---|---|
| Plixorafenib alone (Arm A) | Experimental | Patients will start the study drug (plixorafenib 900mg daily 30 minutes after a full meal or meal supplement) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth continuously for 28-day cycles until progressive disease or up to 24 cycles. MRI will be performed post-operatively (between surgery and start of study drug) for evaluation of measurable disease, at the beginning of Cycle 2, then at the beginning of every odd cycle. Blood and CSF samples will be obtained on day of surgery, C1D1 (baseline), pre-C2 (week 4) and with every odd cycle up to and including C7 and EOT Receives: Drug: Plixorafenib |
| Plixorafenib in combination with retifanlimab (Arm B) | Experimental | Participants will receive one dose of retifanlimab prior to surgery. Following surgery, the participants will start plixorafenib 7-28 days post-operatively, when clinically stable. Retifanlimab (administered by IV every 28 days) will be restarted after one cycle of plixorafenib or after the 2nd cycle of plixorafenib per physician discretion. Patients will take the drugs in 28-day cycles until progressive disease or up to 24 cycles. MRI, blood, CSF and other study assessments will be performed as for Arm A. Receives: Drug: Plixorafenib; Drug: Retifanlimab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Detection rate of BRAF-V600E ctDNA in CSF and/or plasma
Proportion of patients with detectable ctDNA in CSF and/or plasma detected at surgery, baseline (C1D1), and pre-Cycle 2 (week 4).
Measured: surgery, baseline (C1D1) and pre-cycle 2 (week 4)
Secondary outcomes (3)
Compare BRAF-V600 ctDNA levels in CSF and plasma after treatment among patients with different radiographic responses
Quantify disease progression and treatment response rate over time BRAF-V600 ctDNA levels among patients with different radiographic responses (1="improved", 2="stable", 3="worsened" measured by RANO 2.0 criteria) at 4 and 16 weeks after the treatment initiation (pre-C2, pre-C5). Correlation of ctDNA levels in CSF and plasma samples at baseline, after 4 weeks (pre-C2) and 16weeks of treatment with radiographic disease status after 4 (pre-C2) and 16 weeks (pre-C5) of treatment
Measured: up to 16 weeks
Radiographic response rate in each arm
Arm A: Radiographic response by RANO 2.0 criteria at 4 and 16 weeks (pre-C2 \& pre-C5).
Arm B: Radiographic response by iRANO criteria at 4 and 16 weeks pre-C2 \& pre-C5).
Measured: up to 16 weeks
Percentage of patients with serious Treatment-Emergent Adverse Events (TEAEs) treated with plixorafenib alone or in combination with retifanlimab.
CTCAE v5 will be utilized to determine serious TEAEs as outline in the study
Measured: up to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2024
- Study start7 Apr 2025
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BRAF V600E MutationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Sponsor type
- University, hospital or other
- Collaborators
- Fore Biotherapeutics, Ivy Brain Tumor Foundation, Incyte Corporation
- Responsible party
- Sponsor
- Investigators
- Karisa Schreck, MD, Study chair, Johns Hopkins University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06610682
- Sponsor's protocol ID
- J2488
- Other IDs
- IRB00457005, 146958
- Status last verified
- Sep 2026
- First submitted
- 20 Sep 2024
- Last updated
- 22 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No